After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team
What’s up at Boehringer Ingelheim?
After a string of pipeline deals aimed at revitalizing the R&D group, the decidedly private German company is undergoing a high-level makeover of the top team.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.